Breast cancer–specific MRRs stratified by age at diagnosis, California, 2005–2014
Younger (18–49) | Older (50+) | |||||
---|---|---|---|---|---|---|
Number of deaths due to breast cancer | MRR (95% CI)a | MRR (95% CI)b | Number of deaths due to breast cancer | MRR (95% CI)a | MRR (95% CI)b | |
All | 2,236 | 6,233 | ||||
Tumor subtype | ||||||
HR+/HER2– | 820 | Reference | Reference | 2,781 | Reference | Reference |
HR+/HER2+ | 236 | 1.11 (0.96–1.29) | 0.80 (0.69–0.93) | 598 | 1.69 (1.55–1.85) | 1.05 (0.95–1.15) |
HR–/HER2+ | 214 | 2.45 (2.11–2.85 | 1.37 (1.15–1.62) | 476 | 2.86 (2.60–3.16) | 1.28 (1.14–1.43) |
Triple negative | 738 | 3.88 (3.51–4.29) | 2.50 (2.19–2.86) | 1,518 | 4.26 (4.00–4.54) | 2.35 (2.17–2.53) |
Unclassified | 228 | 1.29 (1.11–1.49) | 1.11 (0.96–1.29) | 860 | 1.56 (1.44–1.68) | 1.25 (1.16–1.36) |
P interaction = 0.0008c | ||||||
NCICC | ||||||
No | 1,901 | Reference | Reference | 5,784 | Reference | Reference |
Yes | 335 | 1.08 (0.96–1.22) | 1.00 (0.89–1.13) | 449 | 0.94 (0.86–1.04) | 0.84 (0.76–0.93) |
P interaction = 0.003c | ||||||
Guideline-concordant treatment | ||||||
Yes | 1,409 | Reference | Reference | 2,879 | Reference | Reference |
No | 230 | 1.25 (1.09–1.44) | 1.20 (1.03–1.40) | 657 | 1.47 (1.35–1.60) | 1.49 (1.36–1.63) |
Not available | 590 | 0.32 (0.29–0.36) | 1.00 (0.88–1.15) | 2,683 | 0.31 (0.29–0.32) | 1.14 (1.05–1.24) |
Unknown | 7 | 0.95 (0.45–2.00) | 0.59 (0.27–1.30) | 14 | 1.09 (0.65–1.85) | 0.79 (0.45–1.40) |
P interaction = 0.015c |
↵aAdjusted for year at diagnosis.
↵bStratified by AJCC stage, and adjusted for year of diagnosis, age at diagnosis (continuous), marital status, race/ethnicity, insurance status, nSES, lymph node involvement, tumor size, tumor grade, tumor histology, and clustering by block group.
↵cP for interaction between age group (younger and older) and tumor subtype, NCICC, or guideline-concordant treatment (excluding unknown) from a model which included all significant interactions with age group.